Vaccine discovered for hep C

February 16, 2012 By Jamie Hanlon
Hepatitis C researcher John Law

(Medical Xpress) -- A University of Alberta researcher and Canada Excellence Research Chair in Virology has made the discovery of a vaccine that will potentially help combat hepatitis C. Michael Houghton, who led the team that discovered the hepatitis C virus in 1989, announced his findings at the Canada Excellence Research Chairs Summit in Vancouver this afternoon. Currently, there are no vaccines against the disease available.

Houghton, also the Li Ka Shing Chair in Virology at the University of Alberta, says the vaccine, developed from a single strain, has shown to be effective against all known strains of the virus. It took more than 10 years to develop and started while he was working for the drug company . Following previous vaccine tests funded by the National Institutes of Health that yielded promising results, he said there remained two critical questions.

“Did the recipients actually produce antibodies that could neutralize the actual infectious virus,” he said, “and if they could, how broad was the neutralizing response?”

The challenge, Houghton said, was that hepatitis C is more virulent than HIV, thus coming up with a vaccine that would neutralize the different strains around the world was believed to be impossible. Using a vaccine developed and tested on humans in his University of Alberta lab, Houghton and his co-investigator John Law discovered that the vaccine was capable of eliciting broad cross-neutralising antibodies against all the different major . Houghton says that this finding bodes good news for those with hep C and those who live or travel to areas where the disease is prevalent.

“This tells us that a vaccine made from a single strain can indeed neutralize all the viruses out there,” says Houghton. “It really encourages the further development of that vaccine. This is a really a big step forward for the field of HCV vaccinology.”

With hundreds of thousands of people being infected with C annually, and with between 20 to 30 per cent of those developing some form liver disease, this announcement brings hope. However, Houghton cautions that further testing is required, meaning that it may be five to seven years before the vaccine receives approval. And while it may make some difference in those currently suffering from , it is mainly a preventative measure against acquiring the disease.

The discovery of the by a University of Alberta researcher, and one of the first appointed Canada Excellence Research Chairs is proud news for both organizations.

"A breakthrough such as this one is exactly the kind of advance we believed would happen here when we created the Li Ka Shing Institute of Virology and recruited internationally renowned researchers such as Michael Houghton and his colleagues," said U of A President Indira Samarasekera.

Chad Gaffield, chair of the steering committee for Canada Excellence Research Chairs program said one of the ambitions of the program was to attract world-class talent to Canada, those whose research would be foremost in making the breakthroughs needed in the 21st century. While it may not be obvious when or where such breakthroughs will occur first, Houghton`s discovery illustrates the impact of this program on a national and international scale.

“The premise of the CERC program is that if you support top minds internationally, good things will happen,” he says. “This is a wonderful illustration of how a key problem in the world today becomes much more understandable and solutions are much closer thanks to the work of Michael Houghton.”

The breakthrough underscores the benefit of the U of A’s Li Ka Shing Institute of Virology.

"This demonstrates that the Li Ka Shing Institute is internationally competitive in important areas of virology research,” said Lorne Tyrrell, director of the institute and a leading virologist in his own right. “We are working on topics that are important to patients, and we want to translate discoveries from the lab to patient care. That has been our philosophy since day one. We have a long way to go, but this is a great step.”

The Canada Excellence Research Chairs Program supports Canadian universities in their efforts to build on Canada's growing reputation as a global leader in research and innovation. The program awards world-renowned researchers and their teams up to $10 million over seven years to establish ambitious research programs at Canadian universities. The University of Alberta is home to three of 18 CERCs in Canada. These chairs are in , arctic resources, and oilsands molecular engineering.

Explore further: Possible hepatitis C vaccine

Related Stories

Possible hepatitis C vaccine

September 5, 2007

Hepatitis C Virus (HCV) infects up to 500,000 people in the UK alone, many of the infections going undiagnosed. It is the single biggest cause of people requiring a liver transplant in Britain. Now, in a collaborative effort ...

Insight into HIV immunity may lead to vaccine

May 6, 2011

(Medical Xpress) -- Latest insights into immunity to HIV could help to develop a vaccine to build antibodies’ defences against the disease, a University of Melbourne study has found.

New vaccine for hepatitis C virus

July 28, 2011

Murdoch University researchers have begun a study to develop a new and innovative vaccine for the hepatitis C virus (HCV).

New hope for hep C vaccine

September 13, 2011

Hopes for an effective vaccine and treatment against the potentially fatal hepatitis C infection have received a major boost following the discovery of two 'Achilles' heels' within the virus.

Recommended for you

New drug to fight fatal but neglected tropical disease

August 31, 2016

In a breakthrough for those infected by the parasites that cause sleeping sickness, a young Queensland researcher has identified a compound that kills the parasites in the lab without having any toxic effect on human cells.

Traces of Ebola virus linger longer than expected in semen

August 31, 2016

Initial data from a Liberian public health program show about 9 percent (38) of 429 male Ebola survivors had fragments of Ebola virus in their semen. Of those, 63 percent had semen samples that tested positive for Ebola fragments ...

Researchers discover a drug for a tropical disease

August 30, 2016

Researchers at the University of Georgia are working to find the fastest way possible to treat and cure human African trypanosomiasis, long referred to as sleeping sickness. By working to improve chemical entities already ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.